Marbodin

Memantine hydrochloride, the active ingredient in Marbodin, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adult patients.

GNH USA supplies Marbodin as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine hydrochloride is used in the management of Alzheimer’s disease, targeting the glutamatergic pathway to improve cognitive function.

- Moderate to severe Alzheimer’s disease: improves cognition, memory, and daily functioning. - Alzheimer’s disease‑related behavioral disturbances: may reduce agitation and aggression. - Progressive cognitive decline in Alzheimer’s disease: helps slow functional deterioration.

Memantine is generally well tolerated, but patients may experience adverse reactions.

Common Side Effects: - Dizziness: mild to moderate sensation of light‑headedness. - Headache: transient cranial pain. - Constipation: reduced bowel movements. - Fatigue: feeling of tiredness or lack of energy. - Confusion: temporary mental clouding.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or anaphylaxis. - Hallucinations or psychosis: visual or auditory disturbances. - Seizures: rare occurrence of convulsive episodes. - Cardiac arrhythmias: irregular heart rhythm. - Liver injury: elevated liver enzymes or jaundice.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Assess renal function: monitor kidney function before and during treatment. - Monitor psychiatric status: watch for worsening confusion, hallucinations, or agitation. - Avoid use in patients with known hypersensitivity: discontinue if allergic reaction occurs. - Caution in hypertension: regularly check blood pressure. - Pregnancy and lactation: safety not established; use only if benefit outweighs risk. - Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Memantine may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP450 inhibitors (e.g., ketoconazole): may increase memantine plasma levels. - Amantadine: additive NMDA antagonism can heighten side‑effects. - NMDA agonists: may diminish therapeutic benefit.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may blunt cognitive improvements. - Diuretics: monitor electrolytes and renal function. - Alcohol: may enhance dizziness or sedation.